Results 31 to 40 of about 24,005 (199)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors

Frontiers in Microbiology, 2021
The apicomplexan parasite, Theileria annulata, is the most prevalent hemoprotozoan in livestock, causing significant economic losses worldwide. It is essential to develop new and improved therapeutics, as current control measures are compromised by the ...
Madhumanti Barman, Sonam Kamble, Sonti Roy, Vasundhra Bhandari, Siva Singothu, Debabrata Dandasena, Akash Suresh, Paresh Sharma   +7 more
doaj   +1 more source

HDAC inhibition potentiates immunotherapy in triple negative breast cancer. [PDF]

, 2017
Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various
Ali, Niwa, Budillon, Alfredo, Krings, Gregor, Munster, Pamela N, Park, Jeenah, Pawlowska, Nela, Rosenblum, Michael D, Terranova-Barberio, Manuela, Thomas, Scott   +8 more
core   +1 more source

Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.

PLoS ONE, 2014
Resistance to imatinib (Gleevec®) in cancer cells is frequently because of acquired point mutations in the kinase domain of BCR-ABL. Ponatinib, also known as AP24534, is an oral multi-targeted tyrosine kinase inhibitor (TKI), and it has been investigated
Seiichi Okabe, Tetsuzo Tauchi, Shinya Kimura, Taira Maekawa, Toshihiko Kitahara, Yoko Tanaka, Kazuma Ohyashiki   +6 more
doaj   +1 more source

A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. [PDF]

, 2013
High expression of ERBB2 has been reported in medulloblastoma and ependymoma; EGFR is amplified and over-expressed in brainstem glioma suggesting these proteins as potential therapeutic targets. We conducted a molecular biology (MB) and phase II study to
Blaney, Susan M., Boyett, James M., Fouladi, Maryam, Gajjar, Amar, Geyer, J. Rusell, Gilbertson, Richard J., Goldman, Stewart, Kun, Larry E., Onar Thomas, Arzu, Packer, Roger J., Schaiquevich, Paula Susana, Stewart, Clinton F.   +11 more
core   +1 more source

Vorinostat-An overview

Indian Journal of Dermatology, 2015
Vorinostat is a new drug used in the management of cutaneous T cell lymphoma when the disease persists, gets worse or comes back during or after treatment with other medicines. It is an efficacious and well tolerated drug and has been considered a novel drug in the treatment of this condition.
openaire   +3 more sources

Epigenetic treatment of solid tumours. A review of clinical trials [PDF]

, 2015
Epigenetic treatment has been approved by regulatory agencies for haematological malignancies. The success observe in cutaneous lymphomas represents a proof of principle that similar results may be obtained in solid tumours. Several agents that interfere
CODACCI PISANELLI, Giovanni, DE MARINIS, ELISABETTA, NERVI, Clara   +2 more
core   +2 more sources

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]

, 2014
Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip, Kaseb, Ahmed O, Kurzrock, Razelle, Tsimberidou, Apostolia M, Wolff, Robert A   +4 more
core   +6 more sources

Activation of the Unfolded Protein Response Contributes toward the Antitumor Activity of Vorinostat

Neoplasia: An International Journal for Oncology Research, 2010
Histone deacetylase (HDAC) inhibitors represent an emerging class of anticancer agents progressing through clinical trials. Although their primary target is thought to involve acetylation of core histones, several nonhistone substrates have been ...
Soumen Kahali, Bhaswati Sarcar, Bin Fang, Eli S. Williams, John M. Koomen, Philip J. Tofilon, Prakash Chinnaiyan   +6 more
doaj   +1 more source

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma [PDF]

Journal of Cellular Physiology, 2020
AbstractGlioblastoma (GBM) is an aggressive brain tumor and drug resistance remains a major barrier for therapeutics. Epigenetic alterations are implicated in GBM pathogenesis, and epigenetic modulators including histone deacetylase (HDAC) inhibitors are exploited as promising anticancer therapies. Here, we demonstrate that phospholipase D1 (PLD1) is a
Dong Woo Kang, Won Chan Hwang, Yu Na Noh, Youra Kang, Younghoon Jang, Jung‐Ae Kim, Do Sik Min   +6 more
openaire   +2 more sources

Application of Small Epigenetic Modulators in Pediatric Medulloblastoma [PDF]

, 2018
Medulloblastoma is one of the most frequent among pediatric brain tumors, and it has been classified in various subgroups. Some of them already benefit from quite good therapeutic options, whereas others urgently need novel therapeutic approaches ...
Annalisa Romanelli, Antonello Mai, Antonello Mai, Clemens Zwergel, Giulia Stazi, Giuseppina Catanzaro, Marco Tafani, Sergio Valente, Zein Mersini Besharat   +8 more
core   +2 more sources